Printer Friendly

Xenomics Files Italian National Patent on Testing Technology to Detect HIV and Tuberculosis Using Transrenal DNA; Proprietary Diagnostic Tests Enable Simultaneous Detection and Differentiation of Multiple-Drug Resistant TB and Common TB.

NEW YORK -- Xenomics, Inc. (OTCBB:XNOM), a developer of next-generation medical DNA technologies, has filed a provisional patent in Italy for its breakthrough technology enabling the detection of Transrenal-DNA of HIV and tuberculosis through the safe and non-invasive process of urine sampling. The Italian patent application, which paves the way for the filing of European and American patents, represents the Company's latest step in its business strategy to aggressively expand and protect its intellectual property portfolio.

The Company believes that this application of its patented technology development platform may enable the creation of more sensitive and accurate medical testing methods that can be conducted through the simple, safe and relatively inexpensive diagnostic processes based on urine specimens. The technology also provides breakthrough ability to simultaneously detect both HIV and tuberculosis, a common co-infection in AIDS patients, with a single urine sample, and may hold important implications for the detection and treatment of residual HIV infections. The discovery was made at the Company's joint venture with the National Institute for Infectious Diseases "Lazzaro Spallanzani" in Rome.

Because the technology was developed in Italy, international patent regulations require that the patent be initially filed in that country where the discovery was made. The initial filing will lead to the filing of the broader European patent, and then to the U.S. patent.

"The filing of the provisional patent on our breakthrough detection of TB and HIV-DNA in the urine of AIDS patients marks a continued step in our strategy to aggressively expand the Company's intellectual property portfolio and to protect that property with broad and well-enforced U.S. and international patents," said Dr. Randy White, CEO of Xenomics. "To manage this critical area, we recently established our Department of Licensing and Intellectual Property, and appointed veteran patent agent Dr. David Ladner to lead the department. Through filings such as this, Dr. Ladner is spearheading the expansion of our intellectual property portfolio."

Xenomics is developing and commercializing proprietary gateway DNA testing technology that has the potential to significantly expand the field of molecular diagnostics, currently a $1.5 billion segment of the health care and biotechnology industry. Through its patented Transrenal DNA-based technology platform, the Company is developing a range of tests for infectious diseases including AIDS and tuberculosis, for prenatal genetic testing, including gender determination, Rh incompatibility and Down syndrome, and other applications.

About Xenomics, Inc.

Xenomics is a molecular diagnostic company that focuses on the development of DNA-based tests using Transrenal DNA (Tr-DNA). Xenomics' patented technology uses safe and simple urine collection and can be applied to a broad range of applications, including prenatal testing, tumor detection and monitoring, tissue transplantation, infectious disease detection, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. Scientists from Xenomics were the first to report that fragments of DNA from normal cell death cross the kidney barrier and can be detected in urine. The Company believes that its technology will open significant new markets in the molecular diagnostics field. Xenomics has three issued U.S. patents covering different applications of the technology for molecular diagnostics and genetic testing and a pending European patent for the same applications. The Company has organized a joint venture to conduct research on infectious disease detection with the National Institute for Infectious Diseases (Instituto Nazionale per le Malattie Infettive "Lazarus Spallanzani") in Rome, in the form of a new R&D company called SpaXen Italia, S.R.L. For more information, please visit http://xenomics.com. For more investor-specific information, including daily and historical Company stock quote data and recent news releases, please visit http://www.trilogy-capital.com/tcp/xenomics. To read or download the Company's Investor Fact Sheet visit http://www.trilogy-capital.com/tcp/xenomics/factsheet.html. To view an online video about Xenomics technology and products, visit http://www.trilogy-capital.com/tcp/xenomics/video.html. A TV news report about the Company's next-generation prenatal tests can be viewed at http://www.trilogy-capital.com/tcp/xenomics/ny1_video.html.

Forward-Looking Statements

Certain statements made in this press release are forward looking. Such statements are indicated by words such as "expect," "might," "should," "anticipate" and similar words indicating uncertainty in facts and figures. Although Xenomics believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to be correct. As discussed in the periodic reports of Xenomics, as filed with the Securities and Exchange Commission, actual results could differ materially from those projected in the forward-looking statements as a result of the following factors, among others: uncertainties associated with product development, the risk that Xenomics will not obtain approval to market its products, the risk that Xenomics' technology will not gain market acceptance, the risks associated with dependence upon key personnel, and the need for additional financing.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Apr 1, 2005
Words:806
Previous Article:Sino Silver Completes Acquisition of 60% Interest in Sino-Top Resources & Technologies, Ltd.
Next Article:TechCana Announces its Financial Results for the Second Quarter Ending January 31.


Related Articles
Drug resistance vexes treatment of AIDS.
Rationale and methods for the National Tuberculosis Genotyping and Surveillance Network. (Tubercolosis Genotyping Network).
Multidrug-resistant Mycobacterium tuberculosis in HIV-infected persons, Peru.
Mycobacterium tuberculosis complex drug resistance in Italy.
Predominant tuberculosis spoligotypes, Delhi, India.
New measurable indicator for tuberculosis case detection.
TB ALLIANCE/GLAXOSMITHKLINE TO DEVELOP TB THERAPIES.
Multidrug-resistant tuberculosis detection, Latvia.
Isoniazid preventive therapy and risk for resistant tuberculosis.
Tuberculosis drug resistance and HIV infection, the Netherlands.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters